common kras and braf mutations in colorectal cancer patients
Authors
abstract
background kras and braf gene mutations are considered as key events in carcinogenesis progression of colorectal cancer. given the importance of these gene mutations evaluations, especially in metastatic patients, in terms of determination of therapeutic strategies, we studied the prevalence of kras and braf mutations in tabriz city. materials and methods deoxyribonucleic acid (dna) extracted from fresh tumor and normal tissues of 30 primary crc patients. direct sequencing method, was the method for determining the mutation points of kras exon 2 and braf exon 15 genes. after mutation analysis, the clinical and pathological associations of mutant genes were assessed. results the prevalence of kras gene mutation was 20 %( 6 out of 30 cases) in this study, and none of patients had the mutant braf gene. the odds ratio of the kras gene mutation in high grade crcs was 2.1(95% ci: 1.34 to 3.29). the same ratio for metastasis was 1.1(95% ci: 0.93 to 1.25). there was no significant relationship between the mutation and clinical and pathological aspects of the disease. conclusion the high occurrence of early onset of colorectal cancer in iran demands more attention to screening and prevention programs in the younger age group in the country. however further genetic studies are needed at the molecular level and large population in different geographical areas.
similar resources
KRAS and BRAF mutations in Iranian colorectal cancer patients: A systematic review and meta-analysis
Background: Mutations in the EGFR signaling pathway play an important role in the development of colorectal cancer (CRC). Mutations in these genes, like KRAS and BRAF, affect the treatment strategies and associated with poor prognosis and relative resistance to anti-EGFR therapies. Our aim was to conduct a systematic and meta-analysis on all studies that have been conducted on the prevalence of...
full textColorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond.
With a long-term disease-free survival rate of 35% after multimodal treatment of stages II and III colorectal cancer (CRC) and mean overall survival (OS) of approximately 20 months in the metastatic setting, progress in the management of CRC is faster and the prognosis is better than for other gastrointestinal tumors [1]. Over the last 10 years systemic-targeted therapy has led to hope for furt...
full textKRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study
OBJECTIVES Treatment decision-making in colorectal cancer is often guided by tumour tissue molecular analysis. The aim of this study was the development and validation of a high-resolution melting (HRM) method for the detection of KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer and determination of the frequency of these mutations in the respective population...
full textKRAS and BRAF mutations in serum exosomes from patients with colorectal cancer in a Chinese population
The efficacy of epidermal growth factor receptor- targeted therapy is significantly associated with Kirsten rat sarcoma viral oncogene homolog (KRAS) and B-raf serine/threonine kinase proto-oncogene (BRAF) mutation in patients with colorectal cancer (CRC), for which the standard gene testing is currently performed using tumor tissue DNA. The aim of the present study was to compare the presence ...
full textMolecular pathological epidemiology of colorectal cancer in Chinese patients with KRAS and BRAF mutations
An investigation of interactive effects of exogenous and endogenous factors and tumor molecular changes can lead to a better understanding of tumor molecular signatures in colorectal cancer. We here report a molecular pathological epidemiology study in a large cohort of 945 colorectal cancer patients. Mutations of KRAS (36.6%) and BRAF (3.46%) were nearly mutually exclusive. KRAS-mutated tumors...
full textMutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients
Approximately 45% of metastatic colorectal cancer (mCRC) patients with wild-type KRAS exon 2 are resistant to cetuximab treatment. We set out to identify additional genetic markers that might predict the response to cetuximab treatment. Fifty-three wild-type KRAS exon 2 mCRC patients were treated with cetuximab/irinotecan-based chemotherapy as a first- or third-line therapy. The mutational stat...
full textMy Resources
Save resource for easier access later
Journal title:
گوارشجلد ۲۰، شماره ۱، صفحات ۲۷-۰
Keywords
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023